



Advance Access Publication Date: 20 February 2021
Original Article
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Submitted: 19 October, 2020; Revised: 21 December, 2020
© Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society.
Original Article
Mendelian randomization highlights insomnia as a risk 
factor for pain diagnoses
Martin Broberg1, , Juha Karjalainen1,2,3, FinnGena and Hanna M. Ollila1,3,4,*
1Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland 2Program in Medical 
and Population Genetics, Broad Institute, Cambridge, MA, USA 3Center for Genomic Medicine, Massachusetts 
General Hospital, Boston, MA, USA 4Department of Genetics, Stanford University, Palo Alto, CA, USA
aFor specific list, see Supplementary document 1.
*Corresponding author. Hanna M. Ollila, Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland. Email: hanna.m.ollila@
helsinki.fi.
Abstract
Study Objective: Insomnia has been linked to acute and chronic pain conditions; however, it is unclear whether such 
relationships are causal. Recently, a large number of genetic variants have been discovered for both insomnia and pain 
through genome-wide association studies (GWASs) providing a unique opportunity to examine the evidence for causal 
relationships through the use of the Mendelian randomization paradigm.
Methods: To elucidate the causality between insomnia and pain, we performed bidirectional Mendelian randomization 
analysis in FinnGen, where clinically diagnosed ICD-10 categories of pain had been evaluated. In addition, we used 
measures of self-reported insomnia symptoms. We used endpoints for pain in the FinnGen Release 5 (R5) (N = 218,379), and 
a non-overlapping sample for insomnia (UK Biobank (UKBB) and 23andMe, N = 1,331,010 or UKBB alone N = 453,379). We 
assessed the robustness of results through conventional Mendelian randomization sensitivity analyses.
Results: Genetic liability to insomnia symptoms increased the odds of reporting pain (odds ratio (OR) [95% confidence 
interval (CI)] = 1.47 [1.38–1.58], p = 4.12 × 10−28). Manifested pain had a small effect on increased risk for insomnia (OR [95% 
CI] = 1.04 [1.01–1.07], p < 0.05). Results were consistent in sensitivity analyses.
Conclusions: Our findings support a bidirectional causal relationship between insomnia and pain. These data support a 
further clinical investigation into the utility of insomnia treatment as a strategy for pain management and vice versa.
Key words:  genetics; GWAS; insomnia; Mendelian randomization; pain; sleep disorders
Statement of Significance
In order to further elucidate the connection between insomnia and pain, we performed a two-sample Mendelian random-
ization analysis using summary statistics from genome-wide association studies of sleep and pain. Our results indicate a 
statistically significant bi-directional causal connection between insomnia and pain. The effect of insomnia exposure on 
pain sensation as the outcome was overall more robust than vice versa. The data we present here may be used as support 
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Introduction
Insomnia is a sleep disorder that affects daytime alertness and 
function due to the difficulty of obtaining sufficient sleep [1, 
2]. Clinical insomnia affects approximately 10% of the popu-
lation, and symptoms of insomnia are substantially more 
frequent with up to 30% prevalence in the population [1, 3]. 
Insomnia has been connected both with somatic and psycho-
logical traits, and with pain [2]. Sleep issues have been reported 
in over 50% of chronic pain disorders, while over 40% of indi-
viduals reporting insomnia have reported chronic pain [4, 5]. 
Previous research has suggested that insomnia has a stronger 
impact on the sensation of pain (chronic and clinical), than the 
less clear effect of pain on sleep quality [4, 6]. Indeed, while 
poor sleep in pain-free individuals increases the risk for new-
onset cases of chronic pain sufficient sleep has been linked to 
improved long-term prognosis in those with tension headache, 
migraine, and chronic musculoskeletal pain [4]. Consequently, 
previous evidence suggests a relationship between lack of 
sufficient sleep in general as evidenced in sleep deprivation 
studies where an increase in pain sensation is seen in model 
organisms [7, 8]. For example, a consecutive three-night sleep 
disruption significantly heightened pain perception [9]. In add-
ition, the link between pain and insomnia, has been reported 
in patients as significant comorbidity with pain interference 
and severity [5].
Chronic pain itself, similarly to sleep disorders, is a prevalent 
social and medical health issue spanning several somatic dis-
eases. Furthermore, while pain at different sites of the body and 
caused by different diseases may have different biological eti-
ologies, the sensitivity to perceived pain may be common across 
these different conditions [10–12]. Similarly, earlier genome-
wide association studies (GWASs) on multisite pain from 
originating from different parts of the body identified uniform 
genetic pathways that increase the risk for perceived pain [13]. 
In addition, chronic pain is oftentimes challenging to medically 
manage, highlighting the need for novel treatment strategies. 
The robust prospective relationship between insomnia and dif-
ferent chronic pain conditions described above raise a question 
if insomnia itself has an impact in chronic or acute pain sensa-
tion and if managing sleep should be explored as one option to 
manage pain.
GWASs have become a standard tool for discovering the gen-
etic association and underlying biology of human diseases [14–
16]. In addition, cohorts have emerged where such discoveries 
are possible. In this study, FinnGen, United Kingdom Biobank 
(UKBB), and 23andMe were used. These are large-scale biobanks 
that aim to discover novel disease associations and ultimately 
improve patient health care.
The gold standard to test for a causal effect of an exposure 
on an outcome, such as disease or pain, on medical research 
is randomized controlled trials. An example of such a trial in 
the context of the current study is treatment or improving in-
somnia on having an impact on disease, pain. However, large 
blinded randomized controlled clinical trials may not be either 
feasible, practical or as in the case of insomnia and pain; still 
in the stages of being performed [17, 18]. One option to deter-
mine whether or not a causal association between sleep and 
pain is the Mendelian randomization (MR) analysis, which 
use single nucleotide polymorphisms (SNPs) in individuals 
as instrumental variables to examine the evidence for causal 
relationships between a trait and a disease [17, 19]. MR was 
originally developed as a “one-sample” based analysis, relying 
on individual-level data, which are generally more difficult to 
utilize for researchers and are not used for multiple GWASs 
[20]. Thus, as the SNPs associated with exposure risk traits and 
outcome diseases or conditions are often found in different 
GWASs, the two-sample MR method has been developed. The 
two-sample MR allows for more power by taking advantage of 
large independent cohorts, and summary statistics instead of 
individual-level data [17, 20]. On an epidemiological note, this 
approach is less susceptible to confounders and reverse caus-
ality, because it imposes strict limits on usable instruments; an 
SNP must be associated with the exposure trait, have no direct 
association with the outcome and does not have an association 
with potential confounders [21]. However, as many genetic vari-
ants have associations with multiple traits (pleiotropy) this may 
impact their validity as instruments for MR [22]. These effects 
can be tested for using pleiotropy tests (such as the Egger inter-
cept method) [21–23].
Using these methods and the rationale above, we aimed 
to examine the causal relationships between insomnia and 
pain. To do this, we used bidirectional two-sample MR analysis 
of biobank GWAS summary statistics from GWASs of both 
insomnia and specific different pain diagnoses. The MR ana-
lysis was performed using summary statistics from FinnGen 
(ICD-10 coded pain cohorts) and UKBB and earlier 23andMe 
data (insomnia cohorts). Through this MR analysis we saw a 
significant bi-directional causality between insomnia and dif-
ferent types of pain, but a stronger and more complex impact 
of insomnia on pain than the reverse. The results provided 
in this investigation highlight the significant genetic bidirec-
tional causality between insomnia symptoms and pain, which 
may be investigated further for clinical management of the 
two conditions.
Methods
Genetic associations with insomnia
We obtained GWAS summary statistics for insomnia from two 
cohorts; the United Kingdom Biobank (UKBB) and 23andMe 
based significant (p < 5 × 10−8) SNPs presented by Jansen et al. 
(2019) Supplementary Table S6 [24] and the summary statis-
tics based on the UKBB presented by Lane et al. [1]. The Jansen 
et al. SNPs were used for exposure instruments as it contains 
more independent lead SNPs, whereas the Lane et  al. sum-
mary statistics were used for outcome data. This approach 
avoids overestimating or skewing the estimates of GWAS sig-
nificant variants where data had been included by 23andMe in 
Jansen et al. Classification of individuals into insomnia cases or 
controls in the 23andMe cohort was assessed using scoring of 
answers to a 7-concept sleep-related questionnaire. The UKBB 
used the question “Do you have trouble falling asleep at night, or 
do you wake up in the middle of the night?” [1, 24].
Genetic associations with pain
We used an independent cohort to estimate the genetic associ-
ations with pain in two-sample MR so as to avoid overlap of in-






/sleep/article/44/7/zsab025/6145161 by guest on 07 O
ctober 2021
Broberg et al. | 3
pain summary statistics were collected from the FinnGen 
Release 5 (R5) release (described in detail below), and were com-
prised of cases defined as carrying ICD10 diagnosis codes for 
disorders with a clear pain component including general pain 
(occurring in joints, limbs, neck, head, abdomen, back, similar 
as the categorization in other pain studies as part of overall 
pain [11]. The data comprises a total of 87,242 cases and 131,127 
controls, and in the sub-categories; joint pain, limb pain, ocular 
pain, throat and chest pain, pain in the abdomen and pelvic 
area and low back pain (Supplementary Table S1). We selected 
significant lead SNPs (p  <  5  × 10−8) by removing highly correl-
ated SNPs by linkage disequilibrium (LD) pruning (primary r2 
threshold of 0.6 and a secondary r2 of 0.1) in the FinnGen R5 
general Pain GWAS summary statistics using the FUMA plat-
form [25]. Additionally, we performed proxy SNP detection for 
the Jansen et al. lead SNPs and the FinnGen general Pain SNPs 
using the LDproxy function of the LDlink platform (an r2-value of 
>0.9 was used as a cut-off for using a potential proxy SNP) [26]. 
In total there were only seven significant FinnGen general pain 
lead SNPs used for MR with insomnia. Thus, as a secondary one-
sample analysis further was performed to support the causality 
from pain to insomnia, we used the lead SNPs in the multisite 
chronic pain (MCP) GWAS data produced by Johnston et al. [13]. 
This provided 64 SNPs used in MR with insomnia, increasing the 
power of the analysis. The study focused on chronic pain (pain 
experienced over 3 months) that also occurred in a number of 
sites where this pain was experienced. The MCP cohort is larger 
in a number of individuals (approximately 380,000 UKBB parti-
cipants) and has larger power to examine shared (pleiotropic) 
effects, and provided a larger amount of significant lead SNPs 
for analysis.
FinnGen
Patients and control subjects in FinnGen provided informed 
consent for biobank research, based on the Finnish Biobank 
Act. Alternatively, older research cohorts, collected prior the 
start of FinnGen (in August 2017), were collected based on 
study-specific consents and later transferred to the Finnish 
biobanks after approval by Fimea, the National Supervisory 
Authority for Welfare and Health. Recruitment protocols 
followed the biobank protocols approved by Fimea. The 
Coordinating Ethics Committee of the Hospital District of 
Helsinki and Uusimaa (HUS) approved the FinnGen study 
protocol no. HUS/990/2017.
The FinnGen study is approved by Finnish Institute for Health 
and Welfare (THL), approval number THL/2031/6.02.00/2017, 
amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/ 
2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, 
digital and population data service agency VRK43431/2017-
3, VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance 
Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, 
KELA 70/522/2019, KELA 98/522/2019, and Statistics Finland 
TK-53-1041-17.
The Biobank Access Decisions for FinnGen samples and 
data utilized in FinnGen Data Freeze 5 include: THL Biobank 
BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, 
BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross 
Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, 
Auria Biobank AB17-5154, Biobank Borealis of Northern 
Finland_2017_1013, Biobank of Eastern Finland 1186/2018, 
Finnish Clinical Biobank Tampere MH0004, Central Finland 
Biobank 1-2017, and Terveystalo Biobank STB 2018001.
Mendelian randomization of causality between 
insomnia and general pain
The lead SNPs demonstrated by Jansen et al. were used as gen-
etic proxies for insomnia in a two-sample MR analysis against 
the FinnGen R5 Pain summary statistics. The Jansen et  al.’s 
study included 23andMe data only for calculating the statistic-
ally most significant variants, which we use here as insomnia 
exposure instruments. We therefore used data from Lane et al. 
[1] when examining pain to insomnia effects. This approach 
Figure 1. Mendelian randomization analyses demonstrate stronger associations 
of insomnia with pain than vice versa. Scatterplots showing association of single 
variants and slopes from IVW, MR Egger, and weighted median analyses. Jansen 
et al. insomnia exposure and FinnGen general pain outcome (A), and FinnGen 
pain exposure with Lane et al. insomnia symptoms outcome (B).
Table 1. MR results assessing the causal effect of insomnia on 
FinnGen R5 pain (general)
MR method SNPs OR [95% CI] P
Inverse-variance weighted 231 1.47 [1.38–1.58] 4.12 × 10−28
MR Egger 231 1.31 [0.99–1.73] 5.57 × 10−2
Weighted median 231 1.33 [1.22–1.46] 3.50 × 10−10






/sleep/article/44/7/zsab025/6145161 by guest on 07 O
ctober 2021
4 | SLEEPJ, 2021, Vol. 44, No. 7
avoids overestimating or skewing the estimates of those vari-
ants where data had been included by 23andMe. Furthermore, 
we double-checked for potential weak instrument bias of the 
exposure instruments by calculating their F-statistic [27, 28]. All 
exposure instruments used here had an F-statistic >10. The in-
struments provided by Jansen et al. exhibited an average F of 42, 
Figure 2. Jansen et al. insomnia demonstrates a significant positive effect size on pain outcome. Forest plot of the MR-based effect sizes of Jansen et al. insomnia ex-
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Johnston et  al. an average of 35 and FinnGen general pain in-
struments exhibited an average F of 32. The MR was performed 
using the TwoSampleMR R package [29, 30]. There are multiple 
methods for MR analysis. The ones we focused on in this study 
were inverse-variance weighting (IVW) [31] method, MR Egger 
[22] and weighted median [32]. The IVW method is a weighted re-
gression that averages the association ratio estimates (weights) 
of multiple uncorrelated exposure instruments to the outcome 
to calculate an overall causal estimate, with a pleiotropic inter-
cept term set to zero [22, 32]. The MR Egger method is similar 
to IVW, but it does not set the intercept term to zero, but rather 
estimates it during the calculation [22]. The weighted median 
method provides more weight to instruments with more precise 
causal estimates, more robust to potential outliers than IVW and 
MR Egger but less efficient overall [21, 22, 32]. All three methods 
use the inverse-variance of instruments weights. Statistical sig-
nificance was determined using the IVW method (p < 0.05).
Sensitivity analysis
We tested for pleiotropic effects using the Egger inter-
cept methods as part of the TwoSampleMR package and the 
MR-PRESSO package [33]. The MR PRESSO method is similar to 
IVW and MR Egger, and uses three steps: (1) the calculation of 
pleiotropy using a global test, (2) identifying outliers and re-
moving these to correct the pleiotropy, and (3) a distortion test 
estimating the significance of causal estimates differences before 
and after correcting for outliers [33]. We performed a leave-one-
out analysis to assess whether individual variants had strong 
effects on the MR estimate. We used the FinnGen R5 Pain sub-
categories (Supplementary Table S1) as outcome instruments 
against the Jansen et al. lead SNPs in order to further validate the 
analysis results, and to ensure that no independent (1) location 
of pain or (2) ICD10 code included, would bias the estimates of 
our analysis. Additionally, we also performed pleiotropic effect 
and leave-one-out analysis of Jansen et al. lead SNPs excluding 
those also found to be significantly (p < 5 × 10−8) associated with 
other sleep traits (sleep duration, short sleep, long sleep, daytime 
naps, chronotype and excessive daytime sleepiness) in the UKBB.
Results
Mendelian randomization exhibits bidirectional 
causality between insomnia and pain
Genetically proxied insomnia increased odds of reporting pain 
(OR [95% confidence interval (CI)] = 1.47 [1.38–1.58], P  =  4.12  × 
10−28, Table 1, Figures 1, A and 2). When stratified by pain subtype, 
there were consistently significant effects of genetic liability to 
insomnia on all pain categories (Table 2).
We performed sensitivity analyses to assess for biases in 
our MR estimates. These analyses revealed no significant plei-
otropy (MR Egger intercept test for insomnia exposure with pain 
outcome p  =  0.40, and pain exposure with insomnia outcome 
p = 0.68, Supplementary Table S2).
In addition to effect from insomnia to pain we observed a 
smaller effect from pain to insomnia (OR [95% CI] = 1.04 [1.01–
1.07], p < 0.05, Table 3, Figure 1, B, Supplementary Figure 1), with 
an MR-PRESSO global test p = 0.95 (Supplementary Table S2).
Leave-one-out analysis removing individual Jansen et  al. 
insomnia SNPs (exposure instruments) on the general pain 
outcome demonstrated robust effects from insomnia to pain re-
gardless of which SNPs were removed (Supplementary Figure 2). 
Similar to pleiotropy analysis above, a funnel plot of the IVW 
analysis on the Jansen et al. insomnia SNPs suggested no signifi-
cant pleiotropy (Figure 3). Vice versa, a leave-one-out analysis 
and funnel plot of pain exposure on insomnia outcome sug-
gested no significant pleiotropy (Supplementary Figure 3).
A secondary bi-directional MR analysis using the MCP lead 
SNPs produced by Johnston et al. also demonstrated significant 
bidirectional causality with insomnia without significant pleio-
tropic effects. The MR analysis of MCP to insomnia (Lane et al.) 
produced an IVW OR [95% CI] = 1.32 [1.26–1.38], P = 1.58 × 10−36, 
while the vice versa using Jansen et al. lead SNPs resulted in an 
IVW OR [95% CI] = 1.36 [1.32–1.41], p = 2.04 × 10−81 (Supplementary 
Figure 4, Supplementary Table S3). Comparing Jansen et al. lead 
SNPs with other UKBB sleep trait analyses we found 26 SNPs sig-
nificantly associated with other sleep traits. We removed those 
and re-calculated the potential pleiotropic effect, and obtained 
an Egger intercept p = 0.55 (no significant pleiotropy). We also 
performed a leave-one-out analysis suggesting still a consistent 
robust effect by the SNPs (Supplementary Figure 5).
Discussion
In this Mendelian randomization study using both two-sample 
and one-sample analyses using data from 10 different GWAS 
datasets (Figure 4), we found evidence to support potentially 
casual bidirectional relationships between insomnia and re-
ported pain. The overlap of lead SNPs between Jansen et  al., 
Table 2. MR results assessing causal effects of insomnia on specific pain category cohorts within FinnGen R5
Pain type Cases Controls OR [95% CI] P Bonferroni P
Abdominal and pelvic area pain 49,416 161,968 1.40 [1.30–1.52] 8.30 × 10−18 4.98 × 10−17
Joint pain 13,419 131,550 1.62 [1.44–1.82] 1.65 × 10−15 9.9 × 10−14
Limb pain 12,606 167,641 1.48 [1.31–1.66] 6 × 10−11 3.6 × 10−10
Low back pain 13,178 164,682 1.70 [1.50–1.93] 1.46 × 10−16 8.76 × 10−16
Ocular pain 893 216,919 1.77 [1.22–2.57] 0.003 0.018
Throat and chest pain 24,609 163,123 1.37 [1.24–1.51] 5.58 × 10−10 3.35 × 10−9
Exposure instruments for insomnia from Jansen et. al, Bonferroni corrected p (accounting for six pain types) threshold = 0.05 (corresponding to 0.0083 nominal p).
Table 3. MR results assessing the causal effects of general pain on 
frequent insomnia symptoms (UKBB)
MR method SNPs OR [95% CI] P
Inverse-variance weighted 7 1.04 [1.01–1.07] 0.009
MR Egger 7 1.06 [0.96–1.17] 0.31
Weighted median 7 1.04 [1.01–1.08] 0.016
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Johnston et  al., Lane et  al., and FinnGen was relatively small 
(Supplementary Table S4). All utilized GWAS datasets here have 
corrected for confounding factors such as sex and age. Primarily, 
insomnia symptoms are a risk factor for generalized pain and 
pain in different parts of the body. Conversely, the pain has a 
small but significant effect on insomnia. These results support 
earlier observations from model organisms, from experimental 
sleep deprivation (a primary manifestation of insomnia) studies 
in humans, from prospective epidemiologic studies and clinical 
findings [7–9].
Our results demonstrate that insomnia is significantly 
causal to general pain (Egger intercept p = 0.4, indicating no sig-
nificant pleiotropy). The results are concordant with previous 
findings linking insomnia to pain [2, 5, 7, 8]. Some findings have 
suggested a state of over-activation of pain-inhibitory circuits 
in patients with insomnia, causing pain sensation independent 
from medication, which may relate to the importance of sleep 
to modulate neural development and maintenance [34]. Other 
studies have linked the effects of insomnia on pain to neur-
onal modifications in the caudate nucleus, which is involved 
in pain suppression [6, 35]. This demonstrates the importance 
of treating insomnia in order to alleviate pain.
In the other direction, we report a significant but smaller 
effect of pain on insomnia (Egger intercept p = 0.68, indicating no 
significant pleiotropy). In part, this may be due to only obtaining 
seven lead SNPs from the FinnGen general pain data used for 
MR (64 SNPs from Johnston et al.), whereas the Jansen et al. data 
contained 248 lead SNPs associated with insomnia. Thus, there 
is a significant difference in power between the two different MR 
directions in this bi-directional study, which may be the reason 
Figure 3. Jansen et al. insomnia instruments show no significant pleiotropy or experimental bias. A funnel plot of the IVW analysis for the 231 insomnia SNP instru-






/sleep/article/44/7/zsab025/6145161 by guest on 07 O
ctober 2021
Broberg et al. | 7
for the difference in significances. The Johnston et  al. dataset 
was used to perform a one-sample MR analysis (both datasets 
were obtained using the UKBB cohort) in order to support our 
two-sample MR of FinnGen general pain exposure on insomnia. 
There has been research indicating a significant effect of chronic 
pain on the onset of insomnia symptoms [12, 36]. However, this 
effect seems to be long-term (years) instead of more immediate 
effects of insomnia on pain sensation (days), and seems to be 
a complex condition with some confounding effects by limited 
social participation on the insomnia outcome as highlighted by 
Tang et al. [9, 12, 36]. The social aspect was linked to pain leading 
to reduced participation in social and physical activities that 
generate sleep pressure and sleep promotion [12, 36].
There are limitations to consider in interpreting the results 
of this study. The pain diagnoses in FinnGen are currently 
not divided into chronic or acute pain, and this remains an 
important avenue to further exploration. The difference be-
tween pain types is essential to take into account as acute 
and chronic pain are likely mediated by distinct mechanisms. 
There is also a need to untangle the differences between gen-
etic effects and short-term clinical intervention for treating 
these conditions, and account for possible pleiotropy in MR. 
Conclusively, we have strong indications that sleep manage-
ment in terms of co-occurring insomnia may be a practical 
avenue for future research in clinical managing of pain sen-
sation, while pain management may also reduce insomnia. 
The bidirectional causal link between pain and insomnia 
highlighted this study is supported by more observational 
studies of pain and insomnia, where both traits were found 
to significantly affect each other [6, 37, 38]. The mainten-
ance of good sleep hygiene could thus prove a cost-effective, 
widely available, and safe way to aid in the management of 
pain. However, as discussed by Wei et al., the primary effect of 
treating insomnia may be to avoid enhanced pain sensation 
after a bad night’s sleep, rather than aiming to alleviate the 
immediate pain sensation by a good night’s sleep, and vice-
versa from pain to sleep [6].
Acknowledgments
We thank Iyas Daghlas and Richa Saxena for commenting 
the analysis plan and the manuscript. The authors would like 
to thank the FinnGen consortium for GWAS summary stat-
istics. This work was funded by grants from Finnish Cultural 
Foundation (M.B.), Lastentautien Tutkimussäätiö (M.B.), and the 
Instrumentarium Science Foundation (H.M.O.).
Author contributions
M.B. and H.M.O. conceived and developed the original study de-
sign. M.B. collected the data and performed the computational 
analyses. M.B. and H.M.O. interpreted the results and wrote the 
manuscript.
Conflict of interest statement. The authors have no potential con-
flict of interest.
References
 1. Lane  JM, et  al.; HUNT All In Sleep. Biological and clinical 
insights from genetics of insomnia symptoms. Nat Genet. 
2019;51(3):387–393.
 2. Morin  CM, et  al. Chronic insomnia. Lancet. 
2012;379(9821):1129–1141.
 3. Morin  C, et  al. Epidemiology of insomnia: prevalence, 
self-help treatments, consultations, and determinants 







/sleep/article/44/7/zsab025/6145161 by guest on 07 O
ctober 2021
8 | SLEEPJ, 2021, Vol. 44, No. 7
of help-seeking behaviors. Sleep Med. 2006;7(2):123–130. 
doi:10.1016/j.sleep.2005.08.008
 4. Finan PH, et al. The association of sleep and pain: an update 
and a path forward. J Pain. 2013;14(12):1539–1552.
 5. Alföldi P, et al. Comorbid insomnia in patients with chronic 
pain: a study based on the Swedish quality registry for pain 
rehabilitation (SQRP). Disabil Rehabil. 2014;36(20):1661–1669.
 6. Wei Y, et al. Insomnia really hurts: effect of a bad night’s 
sleep on pain increases with insomnia severity. Front 
Psychiatry. 2018;9:377.
 7. Alexandre C, et al. Decreased alertness due to sleep loss in-
creases pain sensitivity in mice. Nat Med. 2017;23(6):768–774.
 8. Lewin DS, et al. Importance of sleep in the management of 
pediatric pain. J Dev Behav Pediatr. 1999;20(4):244–252.
 9. Tang  NK, et  al. Prevalence and correlates of clinical in-
somnia co-occurring with chronic back pain. J Sleep Res. 
2007;16(1):85–95.
 10. Staud  R. Evidence for shared pain mechanisms in osteo-
arthritis, low back pain, and fibromyalgia. Curr Rheumatol 
Rep. 2011;13(6):513–520.
 11. Kaur  S, et  al. Gender differences in health care utiliza-
tion among veterans with chronic pain. J Gen Intern Med. 
2007;22(2):228–233.
 12. Tang NK, et al. Impact of musculoskeletal pain on insomnia 
onset: a prospective cohort study. Rheumatology (Oxford). 
2015;54(2):248–256.
 13. Johnston  KJA, et  al. Genome-wide association study 
of multisite chronic pain in UK Biobank. PLoS Genet. 
2019;15(6):e1008164.
 14. Bush  WS, et  al. Chapter 11: genome-wide association 
studies. PLoS Comput Biol. 2012;8(12):e1002822.
 15. Marchini J, et al. Genotype imputation for genome-wide as-
sociation studies. Nat Rev Genet. 2010;11(7):499–511.
 16. Hirschhorn  JN, et  al. Genome-wide association studies 
for common diseases and complex traits. Nat Rev Genet. 
2005;6(2):95–108.
 17. Porcu  E, et  al.; eQTLGen Consortium; BIOS Consortium. 
Mendelian randomization integrating GWAS and eQTL data 
reveals genetic determinants of complex and clinical traits. 
Nat Commun. 2019;10(1):3300.
 18. Gill D, et al. The effect of iron status on risk of coronary ar-
tery disease: a Mendelian randomization study-brief re-
port. Arterioscler Thromb Vasc Biol. 2017;37(9):1788–1792.
 19. Mokry LE, et al. Obesity and multiple sclerosis: a Mendelian 
randomization study. PLoS Med. 2016;13(6):e1002053.
 20. Zheng J, et al. Use of Mendelian randomization to examine 
causal inference in osteoporosis. Front Endocrinol (Lausanne). 
2019;10:807.
 21. Slob  EAW, et  al. A comparison of robust Mendelian ran-
domization methods using summary data. Genet Epidemiol. 
2020;44(4):313–329.
 22. Burgess S, et al. Interpreting findings from Mendelian ran-
domization using the MR-Egger method. Eur J Epidemiol. 
2017;32(5):377–389.
 23. Burgess  S, et  al. Guidelines for performing Mendelian 
randomization investigations. Wellcome Open Res. 
2019;4:186.
 24. Jansen  PR, et  al. Genome-wide analysis of insomnia in 
1,331,010 individuals identifies new risk loci and func-
tional pathways. Nat Genet. 2019;51(3):394–403. doi:10.1038/
s41588-018-0333-3
 25. Watanabe  K, et  al. Functional mapping and annota-
tion of genetic associations with FUMA. Nat Commun. 
2017;8(1):1826.
 26. Machiela  MJ, et  al. LDlink: a web-based application for 
exploring population-specific haplotype structure and 
linking correlated alleles of possible functional variants. 
Bioinformatics. 2015;31(21):3555–3557.
 27. Daghlas I, et al. Habitual sleep disturbances and migraine: 
a Mendelian randomization study. Ann Clin Transl Neurol. 
2020:7(12): 2370–2380. doi:10.1002/acn3.51228 
 28. Burgess  S, et  al. Bias due to participant overlap in two-
sample Mendelian randomization. Genet Epidemiol. 
2016;40(7):597–608.
 29. Hemani  G, et  al. The MR-Base platform supports system-
atic causal inference across the human phenome. eLife. 
2018;7:e34408. doi:10.7554/eLife.34408
 30. Hemani G, et al. Correction: orienting the causal relation-
ship between imprecisely measured traits using GWAS 
summary data. PLoS Genet. 2017;13(12):e1007149.
 31. Burgess  S, et  al. Mendelian randomization analysis with 
multiple genetic variants using summarized data. Genet 
Epidemiol. 2013;37(7):658–665.
 32. Bowden  J, et  al. Consistent estimation in Mendelian 
randomization with some invalid instruments 
using a weighted Median estimator. Genet Epidemiol. 
2016;40(4):304–314.
 33. Verbanck M, et al. Publisher correction: Detection of wide-
spread horizontal pleiotropy in causal relationships in-
ferred from Mendelian randomization between complex 
traits and diseases. Nat Genet. 2018;50(8):1196.
 34. Haack M, et al. Pain sensitivity and modulation in primary 
insomnia. Eur J Pain. 2012;16(4):522–533.
 35. Stoffers  D, et  al. The caudate: a key node in the neur-
onal network imbalance of insomnia? Brain. 2014;137(Pt 
2):610–620.
 36. Tang NKY, et al. The role of pain, physical disability, and 
reduced social participation in insomnia onset in com-
munity dwelling older adults: a prospective cohort study. 
The Lancet. 2013;382:S95. doi:10.1016/S0140-6736(13) 
62520–9
 37. Skarpsno ES, et al. Do physical activity and body mass index 
modify the association between chronic musculoskeletal 
pain and insomnia? Longitudinal data from the HUNT 
study, Norway. J Sleep Res. 2018;27(1):32–39.
 38. Uhlig BL, et al. Insomnia and risk of chronic musculoskel-
etal complaints: longitudinal data from the HUNT study, 






/sleep/article/44/7/zsab025/6145161 by guest on 07 O
ctober 2021
